STRMBIO: Valuation, Funding & Investors
STRM.BIO is a biotechnology company developing a non-viral, cell-derived delivery modality that enables safe, targeted, and scalable in vivo delivery of genetic medicines. Its megakaryocyte-derived vesicle (MV) platform focuses on non-viral gene delivery for hematological diseases and in vivo immune and hematopoietic cell engineering, enabling applications in gene editing, RNA therapeutics, and immune cell engineering.
Leadership & Board
- Current Number of Employees
- 16
- Current LinkedIn Followers
- 4,656
Latest Estimated Valuation
- Total Amount Raised
- $8M
- Total Funding Rounds
- 1
- Latest Funding Amount
- $8M
- Latest Funding Round
- Seed Round
Employee Trend
STRMBIO had 16 employees as of October 26, 2026. The number of employees increased by 0 (0.00%) week-over-week.
Social Trend
STRMBIO had 4,656 followers as of October 26, 2026. The number of followers increased by 0 (0.00%) week-over-week.
Funding Round
| Funding Date | Funding Round | Amount Raised | Post-Money Valuation |
|---|---|---|---|
| Jan 07, 2026 | Seed Round | $8.00M | ― |
Investors
| Investor Name | Funding Round |
|---|---|
| Delos Capital | Seed Round |
| Recordati | Seed Round |
| Boehringer Ingelheim Ventures | Seed Round |
| Blue Bay Capital Fund | Seed Round |
Similar Companies
A snapshot of private companies similar to STRMBIO, helping you discover and navigate related company profiles.
Related News and Analysis
